|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Glucagon-like peptide 1 (GLP-1) and its derivatives in the treatment of diabetes显示文摘 | Nauck MA Meier JJ | 2005 | Regul Pept2005，124，： | 1 |
| 2 | Incretins and their analogues as new antidiabetic drugs 显示文摘 | Nauck MA Meier J J Creutzeldt W | 2003 | Drug News Perspect2003，16，7： | 1 |
| 3 | Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and type 2 diabetic subjects as revealed using a new assay for the intact peptide显示文摘 | Deacon CF Nauck MA Meier J | | 0，，： | 1 |
| 4 | Incretins and the development of type 2 diabetes 显示文摘 | Meier JJ Nauck MA | 2006 | Curr Diab Rep2006，6，3： | 1 |
| 5 | Secretion,degradation,and elimination of lucagons-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects显示文摘 | Meier JJ Nanek MA Kranz D | | 0，，： | 1 |
| 6 | Gastric inhibitory pol- ypeptide and glucagon-like peptide-1 in the pathogene- sis of type 2 diabetes显示文摘 | Nauck MA Ballet B Meier JJ | 2004 | Diabetes2004，53，3： | 1 |
| 7 | Glueagon-like peptide-1 (GLP-1) in biolo- gy and pathology显示文摘 | Meier J J Nauek MA | 2005 | Diabetes Metab Res Rev2005，21，2： | 1 |
| 8 | Glucagon-like peptide 1(GLP-1) in biology and pathology 显示文摘 | MEIER JJ NAUCK MA | 2005 | Diabetes Metab Res Rev2005，21，2： | 1 |
| 9 | Glucagon-like peptide 1 (GLP-1) in biology and pathology显示文摘 | Meier JJ Nauck MA | | 0，，： | 1 |
| 10 | Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory poly- peptide in patients with chronic renal insufficiency and healthy control subjects显示文摘 | Meier JJ Nauek MA Kranz D | 2004 | Diabetes2004，53，3： | 1 |
| 11 | Gastric inhibitory polypep-tide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes显示文摘 | Nauck MA Bailer B Meier JJ | 2004 | Diabetes2004，5313，： | 1 |
| 12 | Clinical evaluation of fiber-reinforced fixed bridges显示文摘 | Freilich MA Meiers JC Duncan JP | 2002 | J Am Dent Assoc2002，133，11： | 1 |
| 13 | Medical or surgical therapy for erosive reflux esophagitis: cost - utility analysis using a markov mode显示文摘 | Romagnuolo J Meier MA Sadowski DC | 2002 | Annals of Surgery2002，236，2： | 1 |
| 14 | Glucagon-like peptide 1 (GLP-1)and its derivatives in the treatment of diabetes显示文摘 | NAUCK MA MEIER JJ | 2005 | Regul Pept2005，，： | 1 |
| 15 | Glucagon-like peptide 1 and its derivatives in the treatment of diabetes显示文摘 | Nauck MA Meier JJ | 2005 | Regul Pept2005，，： | 1 |
| 16 | Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide显示文摘 | Deacon CE Nanck MA Meier I | 2000 | J Clin Endocrinol Metab2000，85，： | 1 |
| 17 | Dapagliflozin versus glipizide as add- on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority triM显示文摘 | Nauck MA Del PS Meier J J | 2011 | Diabetes Care2011，34，9： | 1 |
| 18 | Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide显示文摘 | Deacon CF Nauek MA Meier J | 2000 | J Clin Endoerinol Metab2000，85，10： | 1 |
| 19 | Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronie renal insufficiency and healthy control subjects 显示文摘 | Meier JJ Nauck MA Kranz D | 2004 | Diabetes2004，53，3： | 1 |
| 20 | Dapagliflozin versus gli- pizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52- week, double-blind, active-eontrolled noninferiority trial显示文摘 | Nauck MA Del Prato S Meier JJ | 2011 | Dia- betes Care2011，34，9： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员